Zixian Chen

Zixian Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Academic Radiology
Verified
Journal Article
Closed access
XHXiangui He
Xiangui He
YLYuxi Li
Yuxi Li
YWYong Wang
Yong Wang
WTWei Tian
Wei Tian
ZLZhifan Li
Zhifan Li
ZCZixian Chen
Zixian Chen

1 March 2020 in European Journal of Radiology
Verified
Journal Article
Closed access
ZCZixian Chen
Zixian Chen
CCChen Cui
Chen Cui
GYGang Yin
Gang Yin
YJYong Jiang
Yong Jiang
WWWeichun Wu
Weichun Wu
MLMinjie Lu
Minjie Lu

30 August 2025 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
NLNi Liu
Ni Liu
KYKai Yang
Kai Yang
GCGuijuan Cao
Guijuan Cao
ZCZixian Chen
Zixian Chen
GYGang Yin
Gang Yin
MLMinjie Lu
Minjie Lu

21 March 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
YLYuanyuan Liu
Yuanyuan Liu
GXGe Xu
Ge Xu
FSFunan Shi
Funan Shi
JYJing Yang
Jing Yang
RGRuiqiang Gou
Ruiqiang Gou
LCLiang Cao
Liang Cao
Pseudoaneurysm is a rare but lethal complication of acute myocardial infarction. In this study, we present a unique case of a patient with left ventricular free wall rupture detected by cardiac magnetic resonance more than 1 year after a percutaneous transluminal coronary intervention.

20 September 2024 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
毛赵毛毛 赵
毛毛 赵
XNXiaowei Niu
Xiaowei Niu
LBLu Bai
Lu Bai
ZCZixian Chen
Zixian Chen
JZJing Zhao
Jing Zhao
MBMing Bai
Ming Bai

3 June 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
YZYuqiang Zhou
Yuqiang Zhou
ZZZhiliang Zhang
Zhiliang Zhang
SLShasha Liu
Shasha Liu
JNJiang Nan
Jiang Nan
ZZZhuoli Zhang
Zhuoli Zhang
ZCZixian Chen
Zixian Chen
Immune checkpoint inhibitors (ICIs) are pivotal in treating advanced malignancies, including hepatocellular carcinoma (HCC). However, they can trigger immune-related adverse events (irAEs), among which myocarditis is one of the most life-threatening. Herein, we report the case of a 56-year-old man with HCC who developed myocarditis after receiving two cycles of the PD-1 inhibitor sintilimab. The diagnosis was established via cardiac magnetic resonance (CMR) and confirmed by endomyocardial biopsy (EMB). Following treatment with high-dose corticosteroids and supportive therapy, the patient's condition exhibited significant improvement.